Cefazolin, a new semisynthetic cephalosporin antibiotic. II. In vitro and in vivo antimicrobial activity.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D002511:Cephalosporins / Q000494:pharmacology* / Q000627:therapeutic use; D003016:Clostridium perfringens / Q000187:drug effects; D003353:Corynebacterium diphtheriae / Q000187:drug effects; D003470:Culture Media; D004352:Drug Resistance, Microbial; D004355:Drug Stability; D004926:Escherichia coli / Q000187:drug effects; D006863:Hydrogen-Ion Concentration; D007709:Klebsiella / Q000187:drug effects; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D009344:Neisseria gonorrhoeae / Q000187:drug effects; D011485:Protein Binding / Q000187:drug effects; D051381:Rats; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D003470:Culture Media